中国麻风皮肤病杂志 ›› 2019, Vol. 35 ›› Issue (12): 757-761.doi: 10.12144/zgmfskin201912757

• 综述 • 上一篇    下一篇

天疱疮治疗的研究进展

李秀秀,王培光   

  1. 安徽医科大学第一附属医院皮肤性病科,安徽合肥,230022
  • 出版日期:2019-12-15 发布日期:2019-12-25
  • 通讯作者: 王培光,E-mail:wpg2370@163.com

Update of study on the treatment of pemphigus

LI Xiuxiu, WANG Peiguang   

  1. Department of Dermatology and Venerology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022,China
  • Online:2019-12-15 Published:2019-12-25
  • Contact: WANG Peiguang, E-mail:wpg2370@163.com

摘要: 糖皮质激素是治疗天疱疮的首选药物,免疫抑制剂、静脉注射免疫球蛋白、利妥昔单抗、血浆置换、免疫吸附等辅助治疗逐渐用于天疱疮的治疗,特别是难治性天疱疮。这些辅助治疗不仅有助于改善病情,减少疾病的复发,而且可以帮助减少糖皮质激素的用量。此外一些新的免疫疗法未来可能成为天疱疮的替代治疗手段,如修饰的嵌合性抗原受体,T细胞免疫疗法,B细胞激活因子等。本文对以上治疗方法进行了综述。

关键词: 天疱疮, 糖皮质激素, 免疫抑制剂, 静脉注射免疫球蛋白, 利妥昔单抗, 免疫吸附, 血浆置换

Abstract: Although glucocorticoid is the mainstay in the treatment of pemphigus, some adjuvant therapies, such as immunosuppressants, intravenous immunoglobulin, rituximab, plasma exchange, and immunosorbent therapy have been gradually used in the treatment of pemphigus, especially for refractory cases. These treatments not only help to improve the prognosis of the disease and reduce the risk of relapse, but also contribute to sparing of glucocorticoids. Furthermore, some emerging immune therapies, such as chimeric antigen receptor, T lymphocyte immunotherapy and B-cell activating factor, etc. may provide with alternate treatments in the future. The above therapies are reviewed in this paper.

Key words: pemphigus, glucocorticoids, immunosuppressants, intravenous immunoglobulin, rituximab, immunosorbent, plasmapheresis